Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Division of General Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.
Department of Pathology, Medical University of Graz, Graz, Austria; Omics Center Graz, BioTechMed-Graz, Graz, Austria.
J Am Coll Cardiol. 2018 Apr 10;71(14):1540-1549. doi: 10.1016/j.jacc.2018.01.070.
Cardiac troponins are often elevated in patients with skeletal muscle disease who have no evidence of cardiac disease.
The goal of this study was to characterize cardiac troponin concentrations in patients with myopathies and derive insights regarding the source of elevated troponin T measurements.
Cardiac troponin T (cTnT) and cardiac troponin I (cTnI) concentrations were determined by using high sensitivity assays in 74 patients with hereditary and acquired skeletal myopathies. Patients underwent comprehensive cardiac evaluation, including 12-lead electrocardiogram, 24-h electrocardiogram, cardiac magnetic resonance imaging, and coronary artery computed tomography. cTnT and cTnI protein expression was determined in skeletal muscle samples of 9 patients and in control tissues derived from autopsy using antibodies that are used in commercial assays. Relevant Western blot bands were subjected to liquid chromatography tandem mass spectrometry for protein identification.
Levels of cTnT (median: 24 ng/l; interquartile range: 11 to 54 ng/l) were elevated (>14 ng/l) in 68.9% of patients; cTnI was elevated (>26 ng/l) in 4.1% of patients. Serum cTnT levels significantly correlated with creatine kinase and myoglobin (r = 0.679 and 0.786, respectively; both p < 0.001). Based on cTnT serial testing, 30.1% would have fulfilled current rule-in criteria for myocardial infarction. Noncoronary cardiac disease was present in 23%. Using cTnT antibodies, positive bands were found in both diseased and healthy skeletal muscle at molecular weights approximately 5 kDa below cTnT. Liquid chromatography tandem mass spectrometry identified the presence of skeletal troponin T isoforms in these bands.
Measured cTnT concentrations were chronically elevated in the majority of patients with skeletal myopathies, whereas cTnI elevation was rare. Our data indicate that cross-reaction of the cTnT immunoassay with skeletal muscle troponin isoforms was the likely cause.
在没有心脏疾病证据的骨骼肌疾病患者中,心肌肌钙蛋白常升高。
本研究旨在描述肌病患者的心肌肌钙蛋白浓度,并深入了解升高的肌钙蛋白 T 测量值的来源。
通过使用高敏检测方法,测定 74 例遗传性和获得性骨骼肌肌病患者的心肌肌钙蛋白 T(cTnT)和心肌肌钙蛋白 I(cTnI)浓度。患者接受了全面的心脏评估,包括 12 导联心电图、24 小时心电图、心脏磁共振成像和冠状动脉计算机断层扫描。使用商业检测中使用的抗体,在 9 例患者的骨骼肌样本和尸检获得的对照组织中测定 cTnT 和 cTnI 蛋白表达。对相关的 Western blot 条带进行液相色谱-串联质谱分析,以鉴定蛋白质。
cTnT 水平(中位数:24ng/l;四分位距:11 至 54ng/l)升高(>14ng/l)见于 68.9%的患者;cTnI 升高(>26ng/l)见于 4.1%的患者。血清 cTnT 水平与肌酸激酶和肌红蛋白显著相关(r=0.679 和 0.786,均 p<0.001)。基于 cTnT 连续检测,30.1%的患者将符合当前心肌梗死的纳入标准。23%的患者存在非冠状动脉性心脏病。使用 cTnT 抗体,在大约低于 cTnT 分子量 5kDa 的位置,在患病和健康的骨骼肌中均发现阳性条带。液相色谱-串联质谱鉴定了这些条带中存在骨骼肌肌钙蛋白 T 同工型。
在大多数骨骼肌疾病患者中,cTnT 浓度持续升高,而 cTnI 升高罕见。我们的数据表明,cTnT 免疫检测与骨骼肌肌钙蛋白同工型的交叉反应可能是导致这种情况的原因。